LIPLASOME PHARMA ApS: Financial statements 2020
CVR: 29428514
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -133,000 and a net result of DKK -156,000 compared with DKK -33,551,000 the year before. Equity in the 2020 report amounted to DKK 77,000. The solvency ratio was 5.1%.
- Gross Profit
- DKK -133,000
- Profit/Loss
- DKK -156,000
- Equity
- DKK 77,000
- Total Assets
- DKK 1,524,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -133 t. | -156 t. | 77 t. | - |
| 2019 | - | -81 t. | -33.6 mio. | 233 t. | - |
| 2018 | - | -61 t. | -54 t. | 33.8 mio. | - |
| 2017 | - | -65 t. | -55 t. | 33.8 mio. | 0 |
| 2016 | - | -328 t. | -309 t. | 33.9 mio. | 0 |
Official annual report
How creditworthy is LIPLASOME PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
LIPLASOME PHARMA ApS has published its annual report for 2019. Gross profit came to DKK -81,000, and the net result was DKK -33,551,000.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hans-Henrik Horsted Eriksen. The board consists of John Riis Mortensen (chair), Hans-Henrik Horsted Eriksen and Sanjay Kumar Sehgal. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity in the 2025 report amounted to DKK 2,377,000.